Multiple sclerosis (MS) is an autoimmune disease that targets the central nervous system (CNS). MS initially follows a relapsing-remitting course (RRMS) in which acute attacks are followed by a complete recovery. Eventually, 65% of the RRMS patients go on to develop secondary progressive MS (SPMS), characterized by the progressive and irreversible accumulation of neurological disability. It has been proposed that the transition from RRMS to SPMS results from changes in the nature of the inflammatory response and the progressive accumulation of neurodegeneration. To date, however, there is no reliable method to monitor the activity of the different immune and neurodegenerative processes that contribute to MS pathology. Thus, there is a need for biomarkers useful for the diagnosis, treatment and monitoring of MS patients. In this review, we discuss the potential use of lipids and the immune response against them as biomarkers of inflammation and neurodegeneration for MS.
Introduction
Multiple sclerosis (MS) is the leading cause of neurological disability in young adults (Noseworthy et al., 2000; Sospedra and Martin, 2005) . In 85% of the patients, MS initially follows a relapsing-remitting course (RRMS) in which acute attacks are followed by a complete recovery (Compston and Coles, 2008 ). An adaptive immune response against the central nervous system (CNS) is linked to the pathogenesis of RRMS.
Eventually, 65% of the RRMS patients go on to develop secondary progressive MS (SPMS), characterized by the progressive and irreversible accumulation of neurological disability (Compston and Coles, 2008) . The progressive disease course observed in SPMS generally occurs in the absence of new inflammatory lesions, and therapies that target the adaptive immune response on SPMS show limited efficacy, suggesting that other mechanisms play a role in this stage of MS (Rovaris et al., 2006) . Based on these observations, it has been proposed that while both adaptive and innate immune responses contribute to RRMS, sustained activation of CNS innate immunity drives SPMS (Weiner, 2008) . Thus, it is important to quantify the activity of the different pathogenic processes that contribute to the development and progression of MS, to design therapeutic interventions suited to the individual needs of each patient.
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